Physician profile
Kathy Jo Robb
NPI 1639347248
$21,660.04
in general payments reported to CMS, 2019-2025
69 companies · $6,112 in 2025
The $6,112 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,439 · 2022: $3,618 · 2023: $4,326 · 2024: $5,165 · 2025: $6,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,976.70 |
| Education | $627.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,877.69 | 2021-2025 | Rybrevant, Carvykti, Tecvayli |
| Daiichi Sankyo INC. | $1,637.27 | 2021-2025 | Injectafer, Enhertu, Vanflyta |
| Glaxosmithkline, LLC. | $1,440.01 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Astrazeneca Pharmaceuticals Lp | $1,049.17 | 2021-2025 | Calquence, Enhertu, Tagrisso |
| Seagen INC. | $898.02 | 2021-2023 | Adcetris, Tukysa |
| Sobi, INC | $858.34 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $853.56 | 2021-2025 | Fruzaqla, Alunbrig, Iclusig |
| Astellas Pharma US INC | $844.04 | 2022-2025 | Vyloy, Xtandi, Padcev |
| Pfizer INC. | $766.62 | 2021-2025 | |
| Celgene Corporation | $740.09 | 2021-2025 | Reblozyl, Opdualag, Pomalyst |
| Amgen INC. | $739.97 | 2021-2023 | Kyprolis, Blincyto, Xgeva |
| Exelixis INC. | $719.65 | 2021-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $594.67 | 2021-2023 | Imbruvica, Epkinly |
| Stemline Therapeutics INC. | $517.70 | 2023-2025 | Orserdu, Elzonris |
| Eisai INC. | $513.51 | 2021-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $506.42 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $490.47 | 2021-2025 | Reblozyl, Opdivo |
| Novartis Pharmaceuticals Corporation | $448.64 | 2022-2025 | |
| Genzyme Corporation | $419.78 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $385.61 | 2022-2025 | Libtayo |
| Genentech USA, INC. | $377.97 | 2021-2025 | Polivy, Tecentriq, Phesgo |
| Incyte Corporation | $357.26 | 2021-2025 | Jakafi, Niktimvo, Monjuvi |
| Blueprint Medicines Corporation | $331.89 | 2023-2025 | Ayvakit |
| Puma Biotechnology, INC. | $329.65 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $305.79 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Karyopharm Therapeutics INC. | $236.73 | 2021-2024 | Xpovio |
| Pharmaessentia USA Corporation | $210.96 | 2024-2025 | Besremi |
| Sun Pharmaceutical Industries INC. | $210.48 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.76 | 2021-2025 | |
| Array Biopharma INC | $171.91 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Abbvie INC. | $166.45 | 2024-2025 | |
| Amag Pharmaceuticals, INC. | $164.25 | 2021-2022 | |
| Emd Serono, INC. | $151.09 | 2023-2025 | Bavencio, Tepmetko |
| Alexion Pharmaceuticals, INC. | $148.20 | 2021-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $136.41 | 2022-2025 | |
| Genmab U.S., INC. | $126.74 | 2024-2025 | Epkinly |
| Gilead Sciences, INC. | $125.40 | 2023-2025 | Trodelvy |
| Viiv Healthcare Company | $124.95 | 2024 | Cabenuva |
| Secura Bio, INC. | $122.76 | 2021 | |
| Aveo Pharmaceuticals, INC. | $118.82 | 2022 | |
| Caris Mpi, INC. | $99.86 | 2025 | Mi Cancer Seek |
| Agios Pharmaceuticals, INC. | $88.55 | 2024-2025 | Pyrukynd |
| Aadi Bioscience, INC. | $86.69 | 2023 | Fyarro |
| Adc Therapeutics America, INC. | $85.89 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $84.04 | 2023-2024 | Rezlidhia, Tavalisse |
| Dendreon Pharmaceuticals LLC | $81.88 | 2021 | |
| Blue Earth Diagnostics | $66.75 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $66.14 | 2023-2025 | Qinlock, Romvimza |
| Apellis Pharmaceuticals, INC. | $60.93 | 2023 | Empaveli |
| Geron Corporation | $60.27 | 2025 | Rytelo |
| Recordati_rare_diseases_inc. | $45.92 | 2023-2024 | Sylvant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.14 | 2023-2025 | Gilotrif |
| Dova Pharmaceuticals | $37.73 | 2021 | |
| Pharmacosmos Therapeutics INC. | $37.05 | 2022-2025 | Monoferric |
| Syndax Pharmaceuticals, INC. | $33.25 | 2025 | |
| Beigene USA, INC. | $32.74 | 2023 | Brukinsa |
| Cumberland Pharmaceuticals, INC. | $30.31 | 2023 | Sancuso |
| Fennec Pharmaceuticals, INC. | $25.31 | 2025 | Fyarro |
| Immunogen, INC. | $23.09 | 2023 | Elahere |
| Menarini Silicon Biosystems, INC. | $18.56 | 2025 | |
| Myriad Genetic Laboratories, INC. | $18.51 | 2023 | Prolaris |
| Kyowa Kirin, INC. | $17.86 | 2022 | |
| Epizyme, INC. | $17.86 | 2022 | |
| Biogen, INC. | $17.86 | 2021 | |
| Morphosys, US INC. | $17.86 | 2021 | |
| Myovant Sciences INC. | $17.10 | 2021 | |
| Collegium Pharmaceutical, INC. | $16.67 | 2025 | Xtampza |
| Coherus Oncology, INC. | $15.92 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $15.60 | 2023 | Tazverik |
Drugs and devices associated with these payments
Injectafer $759Cabometyx $636Ojjaara $620Enhertu $584Rybrevant $583Reblozyl $485Doptelet $479Carvykti $467Lenvima $425Jemperli $407Orserdu $390Verzenio $371Zejula $371Calquence $343Ayvakit $332Tecvayli $328Darzalex $307Xtandi $303Libtayo $300Imbruvica $297Tukysa $289Epkinly $279Ibrance $270Tagrisso $256Vonjo $255Pluvicto $254Fruzaqla $245Vyloy $244Adcetris $241Keytruda $241Jaypirca $220Besremi $211Erleada $211Alunbrig $188Vanflyta $183Padcev $176Opdivo $171Braftovi $171Talvey $169Polivy $165Lutathera $141Jakafi $137Mektovi $133Ultomiris $130Yonsa $127Odomzo $127Elzonris $127Cabenuva $125Fyarro $112Lorbrena $111Elrexfio $103Opdualag $102Mi Cancer Seek $99.86Zepzelca $88.80Pyrukynd $88.55Tavalisse $84.04Rezlidhia $84.04Inlyta $82.77Niktimvo $78.27Kyprolis $77.87Tecentriq $77.15Nerlynx $72.25Venclexta $69.80Xpovio $68.56Xalkori $66.18Qinlock $66.14Phesgo $63.57Bavencio $62.17Rytelo $60.27Sarclisa $60.12Pomalyst $58.76Blenrep $56.17Talzenna $55.57Trodelvy $51.51Blincyto $50.93Nubeqa $46.11Xofigo $46.11Sylvant $45.92Imfinzi $45.64Zynlonta $45.28Akeega $44.31Balversa $44.31Cablivi $44.29Enjaymo $44.29Elahere $42.03Datroway $41.71Retevmo $41.57Monjuvi $38.79Brukinsa $32.74Sancuso $30.31Elitek $30.27Iclusig $29.14Ziihera $28.75Gilotrif $27.62Romvimza $27.00Wayrilz $25.02Columvi $24.56Lunsumio $24.56Shingrix $23.87Xospata $22.50
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathy Robb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.